1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

J&J’s HIV/AIDS drug Prezista caught in latest recall

 
• By Donna Young

Johnson & Johnson subsidiary Janssen-Cilag International has initiated a recall of 2,000 bottles from five batches of its HIV/AIDS medicine Prezista (darunavir) in the UK, Ireland, Germany, Austria and Canada after trace amounts of a wood preservative, known as tribromoanisole, or TBA, was found in the drug.

Johnson & Johnson subsidiary Janssen-Cilag International has initiated a recall of 2,000 bottles from five batches of its HIV/AIDS medicine Prezista (darunavir) in the UK, Ireland, Germany, Austria and Canada after trace amounts of a wood preservative, known as tribromoanisole, or TBA, was found in the drug.

The firm said it initiated discussions with regulatory authorities after receiving four consumer reports of an uncharacteristic "musty, mouldy" odour with the drug.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapeutic Category

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 
• By Alaric DeArment

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.